Tan, E. M. & Kunkel, H. G. Characteristics of a Soluble Nuclear Antigen Precipitating with Sera of Patients with Systemic Lupus Erythematosus. J. Immunol. 96, 464–471 (1966).
Abdelal, I. T., Zakaria, M. A., Sharaf, D. M. & Elakad, G. M. Levels of plasma cell-free DNA and its correlation with disease activity in rheumatoid arthritis and systemic lupus erythematosus patients. Egypt. Rheumatol. 38, 295–300 (2016).
Koike, Y. et al. Dynamic pathology for circulating free DNA in a dextran sodium sulfate colitis mouse model. Pediatr. Surg. Int. 30, 1199–1206 (2014).
Vrablicova, Z. et al. Nuclear and Mitochondrial Circulating Cell-Free DNA Is Increased in Patients With Inflammatory Bowel Disease in Clinical Remission. Front. Med. 7, 593316 (2020).
González, L. A., Ugarte-Gil, M. F. & Alarcón, G. S. Systemic lupus erythematosus: The search for the ideal biomarker. Lupus 30, 181–203 (2021).
Verstockt, B. et al. Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD—Disease Outcome and Response to Therapy. J. Crohns Colitis 15, 1431–1442 (2021).
Xu, Y. et al. High levels of circulating cell-free DNA are a biomarker of active SLE. Eur. J. Clin. Invest. 48, e13015 (2018).
Truszewska, A. et al. Cell-free DNA profiling in patients with lupus nephritis. Lupus 29, 1759–1772 (2020).
Mondelo-Macía, P., Castro-Santos, P., Castillo-García, A., Muinelo-Romay, L. & Diaz-Peña, R. Circulating Free DNA and Its Emerging Role in Autoimmune Diseases. J. Pers. Med. 11, 151 (2021).
Kubiritova, Z., Radvanszky, J. & Gardlik, R. Cell-Free Nucleic Acids and their Emerging Role in the Pathogenesis and Clinical Management of Inflammatory Bowel Disease. Int. J. Mol. Sci. 20, 3662 (2019).
Duvvuri, B. & Lood, C. Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases. Front. Immunol. 10, 502 (2019).
Bianchi, D. W. & Chiu, R. W. K. Sequencing of Circulating Cell-free DNA during Pregnancy. N. Engl. J. Med. 379, 464–473 (2018).
Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223–238 (2017).
Vermeesch, J. R., Voet, T. & Devriendt, K. Prenatal and pre-implantation genetic diagnosis. Nat. Rev. Genet. 17, 643–656 (2016).
Lo, Y. M. D. et al. Presence of fetal DNA in maternal plasma and serum. Lancet 350, 485–487 (1997).
Bayindir, B. et al. Noninvasive prenatal testing using a novel analysis pipeline to screen for all autosomal fetal aneuploidies improves pregnancy management. Eur. J. Hum. Genet. 23, 1286–1293 (2015).
Van Den Bogaert, K. et al. Outcome of publicly funded nationwide first-tier noninvasive prenatal screening. Genet. Med 23, 1137–1142 (2021).
Lenaerts, L. et al. Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies. EClinicalMedicine 35, 100856 (2021).
van der Meij, K. R. M. et al. TRIDENT-2: National Implementation of Genome-Wide Non-Invasive Prenatal Testing as a First-Tier Screening Test in the Netherlands. Am. J. Hum. Genet. https://doi.org/10.1016/j.ajhg.2019.10.005 (2019).
Mackie, F., Hemming, K., Allen, S., Morris, R. & Kilby, M. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG Int. J. Obstet. Gynaecol. 124, 32–46 (2017).
Suzumori, N. et al. Classification of factors involved in nonreportable results of noninvasive prenatal testing (NIPT) and prediction of success rate of second NIPT. Prenat. Diagn. 39, 100–106 (2019).
Hui, L. & Bianchi, D. W. Fetal fraction and noninvasive prenatal testing: What clinicians need to know. Prenat. Diagn. 40, 155–163 (2020).
Samura, O. & Okamoto, A. Causes of aberrant non-invasive prenatal testing for aneuploidy: A systematic review. Taiwan. J. Obstet. Gynecol. 59, 16–20 (2020).
MacKinnon, H. J. et al. The impact of maternal autoimmune disease on cell-free DNA test characteristics. Am. J. Obstet. Gynecol. MFM 3, 100466 (2021).
Haghiac, M. et al. Increased Death of Adipose Cells, a Path to Release Cell-Free DNA Into Systemic Circulation of Obese Women. Obesity 20, 2213–2219 (2012).
Dabi, Y. et al. Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure. J. Transl. Med. 16, 335 (2018).
Hui, C. Y. Y., Tan, W. C., Tan, E. L. & Tan, L. K. Repeated failed non-invasive prenatal testing in a woman with immune thrombocytopenia and antiphospholipid syndrome: lessons learnt. Case Rep. 2016, bcr2016216593 (2016).
Hui, L., Bethune, M., Weeks, A., Kelley, J. & Hayes, L. Repeated failed non-invasive prenatal testing owing to low cell-free fetal DNA fraction and increased variance in a woman with severe autoimmune disease. Ultrasound Obstet. Gynecol. 44, 242–243 (2014).
Che, H. et al. Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. Clin. Chem. hvac095 https://doi.org/10.1093/clinchem/hvac095 (2022).
Rees, F., Doherty, M., Grainge, M. J., Lanyon, P. & Zhang, W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology 56, 1945–1961 (2017).
Rees, F. et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann. Rheum. Dis. 75, 136–141 (2016).
Shand, A., Chen, J., Selby, W., Solomon, M. & Roberts, C. Inflammatory bowel disease in pregnancy: a population-based study of prevalence and pregnancy outcomes. BJOG Int. J. Obstet. Gynaecol. 123, 1862–1870 (2016).
Kaul, A. et al. Systemic lupus erythematosus. Nat. Rev. Dis. Prim. 2, 1–21 (2016).
Elkon, K. B. Review: Cell Death, Nucleic Acids, and Immunity. Arthritis Rheumatol. 70, 805–816 (2018).
Heitzer, E., Auinger, L. & Speicher, M. R. Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living. Trends Mol. Med. 26, 519–528 (2020).
Jiang, P. & Lo, Y. M. D. The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics. Trends Genet 32, 360–371 (2016).
Goggs, R., Jeffery, U., LeVine, D. N. & Li, R. H. L. Neutrophil-Extracellular Traps, Cell-Free DNA, and Immunothrombosis in Companion Animals: A Review. Vet. Pathol. 57, 6–23 (2020).
Aucamp, J., Bronkhorst, A. J., Badenhorst, C. P. S. & Pretorius, P. J. The diverse origins of circulating cell-free DNA in the human body: a critical re-evaluation of the literature. Biol. Rev. 93, 1649–1683 (2018).
Papayannopoulos, V. Neutrophil extracellular traps in immunity and disease. Nat. Rev. Immunol. 18, 134–147 (2018).
Lood, C. et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat. Med. 22, 146–153 (2016).
Chowdhury, C. S. et al. Elevated Levels of Total Cell-Free DNA in Maternal Serum Samples Arise from the Generation of Neutrophil Extracellular Traps. Fetal Diagn. Ther. 40, 263–267 (2016).
Dinallo, V. et al. Neutrophil Extracellular Traps Sustain Inflammatory Signals in Ulcerative Colitis. J. Crohns Colitis 13, 772–784 (2019).
Maronek, M. et al. Extracellular DNA Correlates with Intestinal Inflammation in Chemically Induced Colitis in Mice. Cells 10, 81 (2021).
Wang, W.-M. & Jin, H.-Z. Role of Neutrophils in Psoriasis. J. Immunol. Res. 2020, 3709749 (2020).
Anani, H. A. A. et al. Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients. Psoriasis Targets Ther. 10, 13–21 (2020).
Xiao, F. et al. NETosis may play a role in the pathogenesis of Hashimoto’s thyroiditis. Int. J. Clin. Exp. Pathol. 11, 537–547 (2018).
Fuchs, T. A. et al. Extracellular DNA traps promote thrombosis. Proc. Natl Acad. Sci. 107, 15880–15885 (2010).
Chan, R. W. Y. et al. Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. Proc. Natl Acad. Sci. 111, E5302–E5311 (2014).
Malíčková, K. et al. Impaired Deoxyribonuclease I Activity in Patients with Inflammatory Bowel Diseases. Autoimmune Dis. 2011, 945861 (2011).
Leffler, J. et al. A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources. Arthritis Res. Ther. 17, 205 (2015).
Chan, R. W. Y. et al. Plasma DNA Profile Associated with DNASE1L3 Gene Mutations: Clinical Observations, Relationships to Nuclease Substrate Preference, and In Vivo Correction. Am. J. Hum. Genet. 107, 882–894 (2020).
Lateef, A. & Petri, M. Managing lupus patients during pregnancy. Best. Pract. Res. Clin. Rheumatol. 27, 435–447 (2013).
Knight, C. L. & Nelson-Piercy, C. Management of systemic lupus erythematosus during pregnancy: challenges and solutions. Open Access Rheumatol. Res. Rev. 9, 37–53 (2017).
Zhang, C., Liang, M., Xu, X., Zhang, X. & Chen, S. Clinical features of new-onset systemic lupus erythematosus in pregnant patients. J. Obstet. Gynaecol. Res. 44, 234–240 (2018).
Grömminger, S. et al. The influence of low molecular weight heparin medication on plasma DNA in pregnant women. Prenat. Diagn. 35, 1155–1157 (2015).
Ma, G.-C., Wu, W.-J., Lee, M.-H., Lin, Y.-S. & Chen, M. Low-molecular-weight heparin associated with reduced fetal fraction and subsequent false-negative cell-free DNA test result for trisomy 21. Ultrasound Obstet. Gynecol. 51, 276–277 (2018).
Torres, J. et al. Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD—Prediction and Prevention of Inflammatory Bowel Disease. J. Crohns Colitis 15, 1443–1454 (2021).